High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs

Daniela D’Angelo1*, Paula Mussnich1, Roberta Rosa2, Roberto Bianco2, Giampaolo Tortora3 and Alfredo Fusco1,4*

Abstract

Background: Development of resistance to conventional drugs and novel biological agents often impair long-term chemotherapy. HMGA gene overexpression is often associated with antineoplastic drug resistance and reduced survival. Inhibition of HMGA expression in thyroid cancer cells reduces levels of ATM protein, the main cellular sensor of DNA damage, and enhances cellular sensitivity to DNA-damaging agents. HMGA1 overexpression promotes chemoresistance to gemcitabine in pancreatic adenocarcinoma cells through an Akt-dependent mechanism.

Methods: To elucidate the role of HMGA1 proteins in chemoresistance we analyzed resistance to conventional drugs and targeted therapies of human colon carcinoma cells (GEO) that are sensitive to the epidermal growth factor receptor inhibitor cetuximab, and express minimal levels of HMGA1 and cetuximab-resistant (GEO CR) cells expressing high HMGA1 protein levels.

Results: GEO CR cells were less sensitive than GEO cells to cetuximab and 5-fluorouracil. GEO CR cells silenced for HMGA1 expression were more susceptible than empty vector-transfected cells to the drugs' cytotoxicity. Similar results were obtained with anaplastic thyroid carcinoma cells expressing or not HMGA1 proteins, treated with doxorubicin or the HDAC inhibitor LBH589. Finally, HMGA1 overexpression promoted the DNA-damage response and stimulated Akt phosphorylation and prosurvival signaling.

Conclusions: Our findings suggest that the blockage of HMGA1 expression is a promising approach to enhance cancer cell chemosensitivity, since it could increase the sensitivity of cancer cells to antineoplastic drugs by inhibiting the survival signal and DNA damage repair pathways.

Keywords: HMGA1, Chemoresistance, Colon cancer, Thyroid cancer

Background

Chemotherapy is one of the most effective tools for the treatment of neoplastic diseases, but it has two relevant drawbacks: 1) it can harm normal cells, and 2) relapse often occurs within 5 years, and recurrent disease is frequently much more resistant to chemotherapy. The advent of new drugs that selectively target specific molecular pathways involved in tumorigenesis or tumor progression, known as “targeted therapy”, has improved patient outcome and survival. However, both conventional chemotherapy and targeted therapies can fail because of acquired drug resistance. Several mechanisms alone or in combination can confer resistance to cancer cells, namely amplification of cell survival signal pathways, increased DNA damage repair, and altered cellular drug uptake, efflux or metabolism [1,2]. However, each mechanism only partially justifies the lack of response observed in cancer patients. Thus, the identification of other mechanisms mediating drug resistance is a challenge of oncological research.

High Mobility Group A (HMGA) proteins are small non-histone chromatin factors that bind the minor groove of AT-rich DNA sequences through three N-terminal basic domains called “AT-hooks”. The HMGA family consists of four members: HMGA1a, HMGA1b and HMGA1c (which are encoded through alternative splicing by the HMGA1 gene) and HMGA2 (encoded by...
the HMGA2 gene) [3,4]. HMGAs are highly expressed during embryogenesis, and low or absent in normal adult tissues. They are overexpressed in almost all human malignant neoplasias, often associated with metastases and a poor prognosis [3]. HMGAs play a key role in chemoresistance. Indeed, HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy [5]. HMGA1 overexpression promotes chemoresistance to gemcitabine in pancreatic adenocarcinoma cells in vitro through an Akt-dependent mechanism. Moreover, HMGA1-silencing promotes gemcitabine-induced cytotoxicity and reduces tumor growth in vivo in a nude mouse xenograft model of pancreatic cancer [6].

Our group also demonstrated the involvement of HMGAs in the pathway of Ataxia-Teleangiectasia-Mutated (ATM) protein, the main cellular sensor of DNA damage. We demonstrated that HMGAs positively regulate ATM expression and the inhibition of HMGA1 expression through an antisense approach drastically decreases cellular levels of ATM in anaplastic thyroid cancer (ATC) cells, resulting in increased sensitivity to genotoxic agents [7].

To determine the role of HMGA1 proteins in chemoresistance we have analyzed the resistance to antineoplastic drugs of (i) the human colon carcinoma cells (GEO) that are sensitive to the epidermal growth factor receptor (EGFR) inhibitors cetuximab (CTX) and gefitinib, and that express barely detectable levels of HMGA1, and (ii) CTX-resistant GEO (GEO CR) cells that express high HMGA1 protein levels and are generated through in vivo continuous treatment with the drug followed by tumor explant and in vitro stabilization of the deriving resistant cancer cell lines [8].

**Methods**

**Drugs and treatment**

Cetuximab was purchased from ImClone Systems. Doxorubicin and 5-Fluorouracil were purchased from Sigma (Sigma Aldrich, St Louis, MO, USA).

LBH589 was kindly provided by Dr. Caraglia. For ATM inhibition experiments, cells were treated with KU-55933 (Calbiochem) (10 μM) for 1 h before the induction of ATM kinase activity.

**Cell lines, expression vector and transfection**

Human GEO and SW48 colon cancer cells and FRO thyroid anaplastic carcinoma cells were from the American Type Culture Collection (Manassas, VA, USA). GEO CR (CTX resistant) cells were established as described previously [9]. Hairpin RNA interference plasmids were from The RNAi Consortium (Sigma Aldrich). The control PLKO.1 plasmid, which has a scrambled non-targeting short-hairpin (sh) RNA sequence, was from SIGMA. FRO shHMGA1, GEO CR shHMGA1 and respective sh NoTargeting control stable clones were generated by transfection of the above indicated plasmids using the Neon™ Transfection System (Life Technologies, Carlsbad, California). The pCEFLHA and the pCEFLHA-HMGA1 vectors are described elsewhere [10]. GEO pCEFL-HA, GEO-HMGA1, SW48 pCEFL-HA and SW48-HMGA1 cells were generated by transfection of the above-indicated plasmids using the Neon™ Transfection System.

Cells were transfected using Neon™ Transfection System (Life Technologies, Carlsbad, California) under the following conditions:

- FRO: Pulse voltage (v): 1450, Pulse Width (ms): 10, Pulse number: 3;
- GEO and SW48: Pulse voltage (v): 1300, Pulse Width (ms): 30, Pulse number: 1.

After transfection, stable clones were selected by exposure to 1 μg/ml of puromycin (GEO CR and FRO) or 800 ng/ml of neomycin (GEO and SW48) in complete medium.

**Protein extraction, western blotting and antibodies**

Cells were lysed in lysis buffer containing 1% NP40, 1mM EDTA, 50mM Tris–HCl (pH 7.5) and 150mM NaCl, supplemented with complete protease inhibitors mixture (Roche, Branford, CT, USA). Total proteins were separated by SDS–polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Amersham, Piscataway, NJ, USA). Membranes were blocked with 5% non-fat dry milk and incubated with the following antibodies: anti-HMGA1 polyclonal antibody, as previously described [10], anti-ATM S1981p (Rockland, Philadelphia, PA, USA), anti-ATM (Ab91) (Abcam Cambridge, MA) β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), (SC-1615; Santa Cruz), anti-Akt, anti Akt S473p and Phospho-p70 S6 Kinase (Thr389) (Cell Signaling, Beverly, MA, USA), anti Caspase-3 (Santa Cruz), anti-phospho-H2AX (ser 139) (Upstate Biotechnology, Lake Placid, NY, USA).

**RNA extraction and quantitative-RT-PCR**

Total RNA was isolated using TRI-reagent solution (Sigma) and reverse transcription was performed according to standard procedures (Qiagen, Valencia, CA, USA). qRT-PCR analysis was performed using the following primers:

- HMGA1 Fw: 5′-CACAACAGGAAGCAACACCA-3′;
- HMGA1 Rv: 5′-AGGACTCTTCGCGAGATG-3′;
- β-actin Fw: 5′-CCAACCGCCGAGAAAACTG-3′;
- β-actin Rv: 5′-CCAGAGGCGTAACAGGGATAG -3′.
Primers for β-actin were used to normalize qRT-PCR data. To calculate the relative expression levels we used the $2^{-\Delta\Delta CT}$ method [11].

**Cell viability assay**

Drug-induced cytotoxicity was quantified by MTS (3-(4,5 dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl-2-(4-sulfophenyl)-2H-tetrazolium) assay (Promega’s Cell-Titer® 96 AQueous One Solution, Promega Fitchburg, WI, USA). Cells were seeded in 96-well plates at 5x10^3 cells per well, then exposed to serial dilutions of the drugs. After 72h absorbance was measured at 490 nm.

**Apoptosis assays**

Cells were treated with 5FU or doxorubicin and apoptosis was quantified by measuring Caspase 3/7 activation using the Caspase-Glo 3/7 assay (Promega).

**Comet assay**

Cells were treated with CTX and allowed to repair the DNA for 0, 18 and 24 hours and then processed for the COMET assay (Trevigen, Helgerman, CT, USA) following manufacturer’s instructions. Cell images were analyzed using COMET Score (TriTek, Annandale, VA, USA). Comet tail moment was used as the measure of DNA damage. In each experiment, 50 comets were measured per experimental point and the mean ± S.D. was reported.

**Statistical analysis**

We used two-way analysis of variance to compare intergroup differences. The significance of differences was determined by analysis of variances followed by Dunnett’s test as post hoc test using Graph Pad Prism 5.0. Data are reported as mean ± SD and p <0.05 was accepted as statistically significant.

---

**Figure 1** HMGA1 overexpression is related to resistance to Cetuximab and 5-Fluorouracil in GEO colon carcinoma cells. (A) Western blot analysis of protein extracts from GEO and GEO CR (Cetuximab Resistant) cells, using HMGA1 and β-actin antibodies. β-Actin was used as loading control (Left Panel). qRT-PCR analysis of HMGA1 mRNA in GEO and GEO CR cells. Relative expression values indicate the relative change in HMGA1 mRNA expression levels between GEO and GEO CR, normalized with β-actin. The error bars represent the mean ± S.D. of three independent experiments performed in triplicate (Right Panel). (B) Dose response curve for GEO and GEO CR cells treated with cetuximab (Left Panel) or 5-fluorouracil (Right Panel). Cells were exposed to the indicated doses of drugs and, after 72 h, absorbance at 490 nm was measured using a microplate reader to evaluate cell viability. The results are expressed as percent relative to the control. Values are the mean ± S.D. of three experiments performed in triplicate. Dose response curves were obtained by nonlinear curve fitting using GraphPad Prism 5.0 program. Note that the concentration is shown as logarithmic function. *p < 0.05 significance level compared with GEO cells. (C) IC50, inhibitory concentration that kills 50% of cell population and Resistance index calculated as IC50 GEO CR/IC50 GEO cell line.
Results

HMGA1 overexpression correlates with increased resistance to drug-induced cytotoxicity

To define the role of HMGA1 in intrinsic and acquired resistance to conventional and biological agents used in cancer therapy, we first analyzed the sensitivity of GEO colon carcinoma cells, showing a very low HMGA1 expression, and of GEO CR cells, expressing abundant HMGA1 levels (Figure 1A), to the antineoplastic drugs CTX and 5-fluorouracil (5FU), which are used to treat colon cancer [8]. As shown in Figure 1C the GEO CR cells were significantly less sensitive than GEO cells to the cytotoxic effect exerted by CTX and 5FU. To determine whether this difference was due to differences in the expression of HMGA1, we stably overexpressed HMGA1 in GEO cells by transfecting them with a construct expressing HMGA1b isoform (GEO-HMGA1 cells) (Figure 2A), and silenced HMGA1 expression in GEO CR cells by transfecting them with a short hairpin RNA (shRNA) targeting the HMGA1 gene (GEO CR shHMGA1 cells) (Figure 2B). As shown in Figure 2C, GEO-HMGA1 cells were less sensitive to CTX and 5FU than GEO cells transfected with empty vector (GEO pCEFL-HA). Consistently, GEO CR shHMGA1 cells were more susceptible than GEO CR transfected with a scrambled no-targeting shRNA (GEO CR pLKO.1 cells).

Moreover, we examined the sensitivity to these drugs of the colon carcinoma cell line, SW48, which expresses...
low HMGA1 levels, transfected with HMGA1 (SW48-HMGA1) (Additional file 1: Figure S1A). As shown in Additional file 1: Figure S1B, SW48-HMGA1 cells were more resistant to the effect of CTX and 5FU than the empty-vector-transfected SW48 cells (SW48 pCEFL-HA cells).

We extended this analysis to FRO cells that derive from a human anaplastic thyroid carcinoma. We transfected these cells with the same construct used to silence HMGA1 in GEO CR cells (FRO shHMGA1) (Figure 3A). We then treated the FRO cells transfected with the empty vector (FRO pKLO.1) and FRO shHMGA1 cells with doxorubicin, that is currently used in the treatment of anaplastic thyroid carcinoma [12] and LBH589 (aka Panobinostat), an inhibitor of HDAC proteins currently undergoing a clinical trial in patients with metastatic medullary thyroid cancer or radioiodine-resistant differentiated thyroid cancer (ClinicalTrials.gov Identifier:NCT01013597). Also in this case, cells overexpressing HMGA1 were more resistant than cells in which the HMGA1 expression was stably silenced (Figure 3B).

We analyzed the apoptotic rate in GEO CR and GEO CR shHMGA1 cells after exposure to 5FU. Drug-induced apoptosis and caspase 3/7 activation were higher in GEO CR shHMGA1 cells than in GEO CR cells (Figure 4A). A similar result was obtained when FRO and FRO shHMGA1 cells were exposed to doxorubicin. Indeed, the apoptotic rate was higher in the FRO shHMGA1 cells in which HMGA1 was silenced than in FRO expressing high HMGA1 levels. Interestingly, procaspase 3 expression decreased earlier in GEO CR shHMGA1 and FRO shHMGA1 cells than in the cells overexpressing HMGA1 after treatment with 5FU and doxorubicin, respectively (Figure 4B).

Overexpression of HMGA1 correlates with activation of the prosurvival pathway
Resistance to gemcitabine in pancreatic adenocarcinoma cells is mediated by overexpression of HMGA1 through
an Akt-dependent mechanism. Indeed, the expression of a dominant Akt construct abrogated the HMGA1-induced increase in chemoresistance to gemcitabine [6]. Therefore, we analyzed the effect of HMGA1-silencing on the Akt pathway in GEO CR cells treated with 5FU. As shown in Figure 5, levels of phospho-Akt and of its downstream effector phospho-p70 were lower in 5FU-treated GEO CR shHMGA1 cells than in GEO CR cells overexpressing HMGA1. Conversely, total Akt protein levels remained unchanged. The same results were obtained in FRO and FRO shHMGA1 cells treated with doxorubicin (Figure 5A).

Subsequently, to define the role of the PI3-K/Akt pathway in the antineoplastic drug resistance of cancer cells overexpressing HMGA1, we silenced Akt with a shRNA in GEO CR and FRO cells overexpressing HMGA1. We then treated these cells with increasing doses of 5FU or doxorubicin, and assessed their viability 72 hours later. As shown in Figure 5B, inhibition of Akt protein synthesis reversed the chemoresistance induced by HMGA1 overexpression. Thus, HMGA1-induced resistance depends on Akt signaling.

**Overexpression of HMGA1 correlates with activation of the DNA-damage response**

We previously demonstrated that HMGA proteins enhance cancer cell resistance to genotoxic agents by promoting ATM expression and the cellular response to DNA damage, thereby shifting ATM signaling from cell death to cell survival [7]. Therefore, we analyzed the phosphorylation status of ATM and its downstream effector γH2AX in GEO CR cells treated with 5FU. As shown in Figure 6A, phospho-ATM and phospho-H2AX levels were lower in the 5FU-HMGA1-silenced cells than in 5FU-treated GEO CR cells. Similarly, phospho-ATM and phospho-H2AX levels were lower in FRO shHMGA1 cells treated with doxorubicin than in FRO cells.

To verify that the absence of HMGA1 expression results in accumulation of DNA damage and enhanced sensitivity to antineoplastic drugs, we pretreated cells overexpressing HMGA1 with KU-55933, a specific inhibitor of ATM, and, 1 hour later, we treated them with increasing doses of 5FU or doxorubicin. The cytotoxic effect of the chemotherapeutic agents was higher in GEO CR and FRO cells treated with KU-55933 than in cells treated with 5FU or doxorubicin (Figure 6B).

It is known that EGFR stimulate DSB repair after irradiation or activation by its ligands [13] and that the ability of tumor cells to repair DNA damage is reduced following EGFR blockade with Cetuximab [14]. Then, to test whether HMGA1 was able to affect DSB repair after CTX exposure, GEO CR cells expressing or not HMGA1 were treated with CTX, and a comet assay was performed to evaluate the DNA-repair ability following drug exposure. Cells were collected after 0, 18 and 24 hours of treatment and the amount of damaged DNA in each cell type was analyzed evaluating the comet tail moment as a measure of the
DNA damage. Interestingly HMGA-silenced cells displayed higher levels of DNA damage after exposure to CTX for 18 hours, compared with GEO CR empty vector. Moreover, after 24 hours HMGA-overexpressing cells were able to almost completely repair the damage, while HMGA-silenced cells still showed significant levels of damaged DNA (Figure 6C).

These data suggest that DSB repair ability is affected by the presence of HMGA1 proteins also after CTX treatment.

**Discussion**

Overexpression of **HMGA1** and **HMGA2** is a general feature of experimental and human malignancies and their overexpression is often correlated with aggressiveness, resistance to conventional anti-cancer therapies and poor prognosis [3].

In this study we have evaluated the role of HMGA1 proteins in resistance to both conventional and biological anti-neoplastic drugs. We found that enforced overexpression of HMGA1 in human colon carcinoma cells GEO, sensitive to CTX and expressing low levels of HMGA1, promoted resistance to CTX and 5FU. Conversely HMGA1-silencing on GEO CR cells abrogated resistance to the above indicated drugs. Similar findings were obtained with FRO cells expressing high HMGA1 levels treated with doxorubicin and LBH589. Accordingly, the HMGA1-silenced cells displayed a higher apoptotic rate and caspase 3/7 activation after exposure to 5FU or doxorubicin. This result is consistent with our previous data showing that the block of HMGA1 expression obtained by using an adenovirus carrying the HMGA1 cDNA in antisense orientation leads thyroid carcinoma cells to apoptotic death [15].

To determine the mechanisms by which HMGA1 promotes drug resistance, we analyzed the Akt-dependent prosurvival signaling. Indeed, previous findings demonstrate that HMGA1 overexpression mediates gemcitabine resistance in pancreatic adenocarcinoma cells through an Akt-dependent mechanism [6], and over-activation of Akt pathway is a poor prognostic factor in cancer [16]. Here,
consistent with previous results, we report that HMGA1 silencing inhibits activation of the Akt pathway after treatment with 5FU or doxorubicin.

We next investigated whether the reduced sensitivity of the HMGA1-overexpressing cells was associated with enhancement of the DNA-damage response, since we previously demonstrated that HMGA1 positively regulates cellular levels of ATM in anaplastic thyroid cancer cells so causing reduced sensitivity to genotoxic agents [7]. Functional interactions have been identified between ATM and growth factor-mediated signaling [17]. In fact, ATM is a nuclear protein kinase that functions as a signal transducer in response to DNA damage, but has also a cytoplasmic localization mediating the activation of Akt through a growth factor-mediated signaling pathway [18]. Therefore, the decreased ATM levels in the presence of HMGA1 overexpression might increase pro-survival Akt signaling after treatment of the cancer cells with the antineoplastic drugs.

It has been reported that stimulation of EGFR after irradiation or activation by its ligands, such as EGF or TGFalpha activate DSB repair [13]. The ability of tumor cells to repair DNA damage is reduced following EGFR blockade with Cetuximab [14], and recently it has been

Figure 6 Overexpression of HMGA1 correlates with the activation of DNA-damage response. (A) Cells were treated with 50 μM of 5-fluorouracil (left panel) or with 500 nM of doxorubicin (right panel) and collected at the indicated time points after drug treatment. Protein extracts were analyzed western blot to evaluate ATM and H2AX phosphorylation. Total ATM levels are also reported. For H2AX loading control see the β-actin panels in Figure 4. (B) Cell viability curve of GEO CR and FRO cells pretreated or not with 10 μM of KU-55933 for 1 hour, and then with increasing doses of 5FU or doxorubicin. Values are the mean ± S.D. of three experiments performed in triplicate. (C) GEO CR pLKO.1 and GEO CR shHMGA1 cells were treated with 1 μM of CTX, collected after 0, 18 and 24 hours of treatment and processed for comet assay. Comets were stained with SYBR Green, visualized by fluorescence microscopy and analyzed by COMET Score software. A representative comet for each experimental point is shown in the left panel. Right panel shows the quantitative analysis using the COMET Score software. *p < 0.05 significance level compared with GEO CR pLKO.1.
demonstrated that the combination of EGFR inhibition and DNA damage-induced therapy increases in vitro and in vivo response of human tumor cells [19].

Here, we report that the ability of GEO CR cells, resistant to CTX, to repair DNA damage is reduced in absence of HMGAI1 proteins. These data support the idea that HMGAI1, inducing an overactivation of DNA damage response, makes less effective the blockade of this pathway by CTX. This mechanism could act in combination with the overactivation of PI3K/AKT prosurvival pathway, widely reported upregulated in CTX-resistant cells [20].

Conclusions

In conclusion, our findings suggest that the block of HMGAI1 proteins could increase the sensitivity of cancer cells to antineoplastic drugs by inhibiting the survival signal and DNA damage repair pathways, the overactivation of which is a hallmark of resistance to anticancer therapies and a poor prognostic factor in cancer progression. Therefore, the targeted suppression or inactivation of HMGAI1 could be a potential therapeutic strategy with which to increase chemosensitivity in cancer cells.

Additional file

Additional file 1: HMGAI1 overexpression in SW48.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

DD and AF conceived the study. DD, PM and RR designed and performed the assays. DD drafted the manuscript. DD and AF wrote and edited the manuscript. RB and GT edited the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by grants from AIRC (IG 11477) and the Ministero dell’Universita` e della Ricerca Scientifica e Tecnologica – MIUR (PRIN2008). DD is recipient of a fellowship from the Fondazione Italiana per la Ricerca sul Cancro (FIRC). We thank Mario Berardone for the art-work.

Additional file

Additional file 1: HMGAI1 overexpression in SW48.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

DD and AF conceived the study. DD, PM and RR designed and performed the assays. DD drafted the manuscript. DD and AF wrote and edited the manuscript. RB and GT edited the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by grants from AIRC (IG 11477) and the Ministero dell’università e della ricerca scientifica e tecnologica – MIUR (PRIN2008). DD is recipient of a fellowship from the Fondazione Italiana per la Ricerca sul Cancro (FIRC). We thank Mario Berardone for the art-work. We are grateful to Jean Ann Gilder (Scientific Communication srl, Naples, Italy) for substantial editing of the text.

Author details

1Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o, Università di Napoli Federico II, Via Pansini 5, 80131 Naples, Italy. 2Dipartimento di Medicina Clinica e Chirurgia, Università di Napoli Federico II, Naples, Italy. 3Medical Oncology, G.B. Rosal’ Academic Hospital, University of Verona, Verona, Italy. 4Istituto Nazionale di Càncer - INCa, Rio de Janeiro, RJ, Brasil.

Received: 5 May 2014 Accepted: 6 November 2014

References

1. Luqmami YA: Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005, 14(Suppl 1):35–48.
2. Roberti A, La Sala D, Cinti C: Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol 2006, 207:571–581.
3. Fusco A, Fedele M: Roles of HMGAI proteins in cancer. Nat Rev Cancer 2007, 7:899–910.
4. Fedele M, Fusco A: HMGAI and cancer. Biochim Biophys Acta 2010, 1799:48–54.
5. Summer H, Li Q, Bao Q, Zhan L, Peter S, Sathyajithanathan P, Henderson D, Konisch T, Goodman SD, Dröge P: HMGAI2 exhibits DRAP/ApP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy. Nucleic Acids Res 2009, 37:4371–4384.
6. Liu S, Wang E: HMGAI2 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res 2008, 14:14(S):1470–1477.
7. Palmiari D, Valentinato T, D’Angelo D, De Martino I, Postiglione I, Pacelli R, Croce CM, Fedele M, Fusco A: HMGAI proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents. Oncogene 2011, 7:30:273024–3035.
8. Van Cutsem E, Köhne CH, Hitre E, Zakuski J, Chang Chien CR, Makhson A, D’Haens G, Pintér T, Lim R, Bodeky G, Roh J, Koppleme G, Ruff P, Stroh C, Teig S, Schlichting M, Nippen J, Roujier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408–1417.
9. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita V, De Placido S, Bianco AR, Tortora G: Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to anti-epidermal growth factor receptor therapy. Clin Cancer Res 2004, 10:764–769.
10. Perantoni CA, Fedele M, Pentimalli F, Bonenuto G, Per R, Voglietti G, Santoro M, Chiariotti L, Fusco A: High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth. Oncogene 2001, 20(43):6132–6141.
11. Livak KJ, Schmittgen TD: Analysis of relative gene expressiondata using real-time quantitative PCR and the 2(\Delta\Delta CT) method. Methods 2001, 25:402–408.
12. Haugen BR: Management of the patient with progressive radiolodine non-responsive disease. Semin Surg Oncol 1999, 16:34–41.
13. Szymiel E: Epidermal growth factor receptor and DNA double strand break repair: the cell’s self-defence. Cell Signal 2006, 10:1537–1548.
14. Kriegs M1, Nastem-Pisula U, Riekmann T, Holst K, Saker J, Dahn-Daphi J, Dikomey E: The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining. DNA Repair (Amst) 2010, 9(8):889–897.
15. Scala S, Portella G, Fedele M, Chiapporta G, Fusco A: Adenovirus-mediated suppression of HMGAI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci U S A 2000, 97(18):9426–9426.
16. Granville CA, Memmott RM, Gills JI, Dennis PA: Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006, 12:789–798.
17. Valerie K, Yacoub C, Hagan MP, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, Dent P: Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 2007, 6:789–801.
18. Viniegra JG, Martinez N, Modirasan P, Hernandez Loza J, Parada Cobo C, Sánchez-Avilaco Lobo VJ, Acosts Luquej CI, Álvarez-Vallina L, Ramón y Cajal S, Rojas JM, Sánchez-Prieto R: Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem 2005, 280:4029–4036.
19. Lee MJ1, Ye AS, Gardino AK, Sgourakis N, MacBeath G, Yaffe MB: Sequential application of anticaner drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012, 149(4):782–794.
20. Bianco R, Rosa R, Damiano V, Danieli G, Geland T, Garofalo S, Tarallo V, De Falco S, Melisi D, Benelli R, Albini A, Ryan A, Ciardiello F, Tortora G: Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res 2008, 14(16):5069–5080.

Cite this article as: D’Angelo et al.: High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs. BMC Cancer 2014 14:851.